Clindamycin Resistance

The rising level of clindamycin resistance in skin and soft tissue infections has generated increasing concern in the healthcare community. As the lines between community and hospital-acquired strains S. aureus continue to blur, clinicians need a diagnostic platform that is capable of assessing patients for clindamycin susceptibility or resistance in skin and soft tissue infections.

MicroPhage proposes to have the first product to rapidly identify these strains through our easy-to-use bacteriophage amplification platform. Designed to work in parallel with the MicroPhage MRSA/MSSA Skin and Soft Tissue Test, the MicroPhage Clindamycin Test will enable clinicians to rapidly and directly determine if a known S. aureus is susceptible or resistant to clindamycin.

By providing definitive identification faster than standard diagnostic methods, as well as critical antibiotic susceptibility and resistance information, the MicroPhage test will enable physicians to prescribe the most effective treatment right from the start.

Enable the most-appropriate treatment – Use with the MicroPhage MRSA/MSSA Skin and Soft Tissue Infection Test to get critical identification and antibiotic susceptibility and resistance information.
Get definitive results faster than standard diagnostic methods – Receive culture-quality results in hours, not days.
Benefit from an easy-to-use platform – Go direct from a sample – without the need for expensive equipment, batching, or specialized personnel.
Improve outcomes – Reduce treatment delays, complications, and costs.
Simplify testing with a phenotypic test – Rely on viable bacteria for results that are directly related to the sample – no primers or molecular markers.

This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.